Codiak BioSciences Inc

Codiak BioSciences — Corporate Update (June 2022)

26 slides from Codiak BioSciences's corporate update, Jun 30, 2022

  1. Slide 1: exoSTING and exoIL-12 Clinical Update and Future Directions

    June 30, 2022 exoSTINGTM and exoIL-12TM CLINICAL UPDATE and FUTURE DIRECTIONS Exhibit 99.2

  2. Slide 2: Forward-Looking Statements and Disclaimers

    Forward-Looking Statements and Disclaimers These slides and the accompanying presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “antic

  3. Slide 3: Achieved Intended Study Outcomes for this Data Release

    Local retention and lack of systemic exposure of IL-12 Improved safety vs rIL-12 Confirmation of anti-tumor activity Deep and durable effects on injected and abscopal lesions RP2D in optimal study population GO to Phase 2 study 100-fold improved potency vs free STING agonist (SA) Lack of systemic SA

  4. Slide 4: exoIL-12: Clinical Data Update

    exoIL-12TM: Clinical Data Update

  5. Slide 5: exoIL-12 Best-in-Class IL-12 Strategy

    Despite clinical activity in multiple tumor types, IL-12 historically has had an Intolerable AE profile & dose limiting toxicity Narrow to nonexistent therapeutic window Several attempts to localize delivery via AAV, plasmid, mRNA Immuno-cytokine masking and local activation Surface display leveragi

  6. Slide 6: exoIL-12 Two-part Design in Healthy Volunteers and Early Stage CTCL Patients

    exoIL-12TM | Two-part Design in Healthy Volunteers and Patients with Early Stage CTCL PART A – HEALTHY VOLUNTEERS – SAD Screening DLT Safety PK Biomarkers PD Dosing Labs Biopsy Dosing PART B – CTCL STAGE IA-IIB – MAD Screening DLT Safety PK Biomarkers PD Dosing Labs Biopsy Dosing Clinical Activity C

  7. Slide 7: exoIL-12: No systemic release of IL-12, enabling safety profile

    exoIL-12TM: No systemic release of IL-12, enabling safety profile N=2 Dose: 6 mcg N=14 Weeks Plasma IL-12 Level Healthy Volunteers CTCL Patients Limit of quantification: 8 pg/mL All data points below limit of quantification (LOQ) exoIL-12 Dose

  8. Slide 8: Minimal Induction of Systemic IFN following Single and Repeat Dosing

    Minimal Induction of Systemic IFN following Single and Repeat Dosing in Healthy Volunteers and CTCL Patients Healthy Volunteers (SAD) CTCL Patients C1D1 C2D1 C2D15 C1D15 N=2 Dose: 6 mcg N=14 exoIL-12 Dose

  9. Slide 9: exoIL-12: Demonstrates Potential Best-in-Class Safety Profile

    exoIL-12TM : Demonstrates Potential Best-in-Class Safety Profile Current Safety Database 2 CTCL patients, each have received ~20 injections (6µg) to multiple lesions Duration of therapy >6 months 14 healthy volunteers administered single doses between 0.3-12µg Adverse Event Data No treatment-related

  10. Slide 10: exoIL-12: Deep and Durable Responses in Injected and Uninjected Lesions

    exoIL-12TM: Deep and Durable Responses in Injected and Uninjected Lesions Pt 102-001 (stage IIB) Pt 102-002 (Stage IA) Interim data Data cut-off 10 June 2022 exoIL-12 injection Week Week Right Thigh Left Thigh Stomach Left P Thigh R Arm Right Buttock Left Buttock Right Thigh

  11. Slide 11: exoIL-12: Observed Lesion Resolution in Pt 102-001

    exoIL-12: Observed Lesion Resolution in Pt 102-001 Pre Dose C4D1 Target Lesion 1 Target Lesion 1 Target Lesion 2 Target Lesion 2 Patient 102-001

  12. Slide 12: exoIL-12: Observed Reduction in Disease Burden

    exoIL-12TM: Observed Reduction in Disease Burden mSWAT= (%BSA Patch) + (%BSA Plaque x 2) + (%BSA Tumor x 4) Pt 001: >36 weeks on study; Partial Response, all lesions resolved. Remains on study for observation only. Pt 002: >20 weeks on study: Remains on study and continues to receive injections. Dat

  13. Slide 13: exoIL-12: Preliminary Safety and Clinical Activity in CTCL Patients

    exoIL-12TM: Preliminary Safety and Clinical Activity in CTCL Patients PROPRIETARY INFORMATION OF CODIAK BIOSCIENCES | Tumor retention of IL-12, no systemic exposure No systemic inflammatory cytokine related AEs Favorable safety and tolerability profile following multiple administrations of exoIL-12T

  14. Slide 14: Prioritized Clinical Development Strategy

    Prioritized Clinical Development Strategy Expand POC into other indications Combination with SOC (e.g. Merkel, melanoma, cSCC, Kaposi’s) Strengthen POC in CTCL Monotherapy in Stage II-III Combination in Stage III-IV Expand to neoadjuvant indications Combination with SOC in TNBC 6 µg will be utilized

  15. Slide 15: exoSTING: Clinical Data Update

    exoSTINGTM: Clinical Data Update

  16. Slide 16: exoSTING | Novel, Differentiated STING Agonist

    exoSTING™ |Novel, Differentiated STING Agonist Challenges of Free STING Agonists (FSAs) STING agonist targeted to tumor APC 100-fold potency increase, drug retention Lack of systemic STING agonist exposure Innate and adaptive immune activation T-Cell expansion/preservation Local and distal tumor res

  17. Slide 17: Phase 1 Dose Escalation Study of Intratumoral exoSTING in R/R Solid Tumors

    Phase 1 Dose Escalation Study of Intratumoral exoSTINGTM in Unselected Patients with R/R Solid Tumors Screening DLT CDK-002 Biomarkers PK/PD Dosing Labs Biopsy CT Scan Dosing Clinical Activity Safety Cycle 3+ Cycle 1 Cycle 2 DOSE ESCALATION, “3+3” DESIGN HNSCC, oral cavity Sarcoma, chondroid cSCC HC

  18. Slide 18: exoSTING | No Systemic Exposure at Evaluated Doses

    exoSTING™|No Systemic Exposure at Evaluated Doses Free STING Agonist (FSA) Meric-Bernstam et al., Clinc Cancer Res 2021 ADU-S100 Doses: 50, 100, 200, 400, 800. 1600, 3200 and 6400 mcg N=47 Codiak has not conducted a clinical comparison (n=4) (n=3) (n=6) (n=5) (n=3) exoSTING™ *all patients who receiv

  19. Slide 19: exoSTING | Best-in-Class Safety Profile

    0.3 ug (n=4) 1 ug (n=3) 3 ug (n=6) 6 ug (n=7) 12 ug (n=3) Overall (n=23) Subjects with TEAEs 4 (100) 2 ( 66.7) 6 (100) 5 (71.4) 3 (100) 20 (87.0) Subjects with treatment-related AEs 3 ( 75.0) 1 ( 33.3) 4 (66.7) 4 (57.1) 2 (66.7) 14 (60.9) Subjects with treatment-related AEs of Grade 3 or higher* 0 0

  20. Slide 20: exoSTING | Dose Dependent STING Pathway Activation Without High Dose Inhibition

    exoSTING™| Dose Dependent STING Pathway Activation Without High Dose Inhibition MK-1454 Free STING Agonist (FSA) Dose expansion at 540 mcg MK-1454 Abstract, ESMO 2019 IP-10/ CXCL10 Codiak has not conducted a clinical comparison. exoSTING CXCL10 mRNA N=19* *all patients who received ≥ 1 dose STING pa

  21. Slide 21: exoSTING | Induces Increases in CD8 Effector T-cells and PD-L1 in the Tumor

    exoSTING™ | Induces Consistent Increases in CD-8 Effector T-cells and PD-L1 in the Tumor Micro-environment Significant (>2 fold) T-cell infiltration and PD-L1 increase observed 6 of 7 subjects demonstrated increase in PD-L1 4 of 7 subjects demonstrated increased CD8 T-cell infiltration Consistent in

  22. Slide 22: exoSTING | Demonstrates Tumor Regression in Heavily Pre-treated Patients

    exoSTING™| Demonstrates Tumor Regression in Heavily Pre-treated Patients All target lesions (RECIST V1.1) Interim data Data cut-off June 10 2022

  23. Slide 23: exoSTING: Best-In-Class STING Agonist Profile

    exoSTINGTM: Best-In-Class STING Agonist Profile PROPRIETARY INFORMATION OF CODIAK BIOSCIENCES | Tumor retention of STING agonist, no systemic exposure Favorable safety and tolerability profile at doses tested Innate and adaptive immune activation PD dose response without T cell inhibition/ablation A

  24. Slide 24: Rationale for Bladder Cancer

    Rationale for Bladder Cancer Limited tumor burden in early-stage disease IT administration exposes entirety of tumor burden to exoSTING IT administration fits with standard urologic practice patterns Activation of STING pathway could lead to increased sensitivity to CPI therapies pCR rates in neoadj

  25. Slide 25: Clinical Validation of the engEX Platform; GO Decision Achieved with Both Programs

    Tumor retention of exo-therapies, no systemic exposure seen Favorable safety and tolerability profile at doses tested Antitumor activity in both injected and uninjected/distal lesions Clear differentiation and potential best-in-class therapies Phase 1 study objectives achieved Clinical development a

  26. Slide 26: coBiak ‘ lis : ‘ RMATION OF CODIAK BIOSCIENCES |

    coBiak ‘ lis : ‘ RMATION OF CODIAK BIOSCIENCES | —_— ———

Codiak BioSciences — Corporate Update (June 2022) on 6ix